Stock Track | OPKO Health Soars 5.52% in Pre-market on Robust Q4 Results and Pipeline Progress

Stock Track

Feb 28, 2025

Shares of OPKO Health (OPK) surged 5.52% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 results and significant progress in its pharmaceutical pipeline.

The biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for the fourth quarter of 2024, a notable improvement from a net loss of $66.5 million in the same period last year. This positive turnaround was driven by several key factors:

1. Strong growth in the Pharmaceutical segment, with revenue increasing by 39% year-over-year to $80.5 million, boosted by higher product sales and milestone payments from collaborations.

2. Significant progress in OPKO's proprietary ModeX pipeline, with two programs entering Phase 1 clinical trials, including a tetraspecific antibody (MDX-2001) for solid tumors and a nanoparticle vaccine for Epstein-Barr Virus (EBV) in collaboration with Merck.

3. Improved financial position and capital structure, supported by a $50 million upfront payment from the Merck collaboration and the sale of GeneDx, allowing OPKO to fund its pipeline advancement and initiate share buybacks.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141419239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141419239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141419239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141419239","market":"hk","top_or_hot":-1,"title":"Stock Track | OPKO Health Soars 5.52% in Pre-market on Robust Q4 Results and Pipeline Progress","media":"Stock Track","content":"<p>Shares of OPKO Health (OPK) surged 5.52% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 results and significant progress in its pharmaceutical pipeline.</p>\n\n<p>The biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for the fourth quarter of 2024, a notable improvement from a net loss of $66.5 million in the same period last year. This positive turnaround was driven by several key factors:</p>\n\n<p>1. Strong growth in the Pharmaceutical segment, with revenue increasing by 39% year-over-year to $80.5 million, boosted by higher product sales and milestone payments from collaborations.</p>\n\n<p>2. Significant progress in OPKO's proprietary ModeX pipeline, with two programs entering Phase 1 clinical trials, including a tetraspecific antibody (MDX-2001) for solid tumors and a nanoparticle vaccine for Epstein-Barr Virus (EBV) in collaboration with Merck.</p>\n\n<p>3. Improved financial position and capital structure, supported by a $50 million upfront payment from the Merck collaboration and the sale of GeneDx, allowing OPKO to fund its pipeline advancement and initiate share buybacks.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | OPKO Health Soars 5.52% in Pre-market on Robust Q4 Results and Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | OPKO Health Soars 5.52% in Pre-market on Robust Q4 Results and Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of OPKO Health (OPK) surged 5.52% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 results and significant progress in its pharmaceutical pipeline.</p>\n\n<p>The biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for the fourth quarter of 2024, a notable improvement from a net loss of $66.5 million in the same period last year. This positive turnaround was driven by several key factors:</p>\n\n<p>1. Strong growth in the Pharmaceutical segment, with revenue increasing by 39% year-over-year to $80.5 million, boosted by higher product sales and milestone payments from collaborations.</p>\n\n<p>2. Significant progress in OPKO's proprietary ModeX pipeline, with two programs entering Phase 1 clinical trials, including a tetraspecific antibody (MDX-2001) for solid tumors and a nanoparticle vaccine for Epstein-Barr Virus (EBV) in collaboration with Merck.</p>\n\n<p>3. Improved financial position and capital structure, supported by a $50 million upfront payment from the Merck collaboration and the sale of GeneDx, allowing OPKO to fund its pipeline advancement and initiate share buybacks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPK","symbol_name":"Opko Health","start_time":0,"source_url":"","article_id":"1141419239","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141419239","pubTimestamp":1740753035,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of OPKO Health  surged 5.52% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 results and significant progress in its pharmaceutical pipeline.The biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for the fourth quarter of 2024, a notable improvement from a net loss of $66.5 million in the same period last year. This positive turnaround was driven by several key factors:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPK":"Opko Health"},"translate_title":"由于强劲的第四季度业绩和管道进展，OPKO Health盘前飙升5.52%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPK":1},"content_text":"Shares of OPKO Health (OPK) surged 5.52% in pre-market trading on Friday, following the company's impressive fourth-quarter 2024 results and significant progress in its pharmaceutical pipeline.\nThe biopharmaceutical company reported a net income of $14 million, or $0.01 per diluted share, for the fourth quarter of 2024, a notable improvement from a net loss of $66.5 million in the same period last year. This positive turnaround was driven by several key factors:\n1. Strong growth in the Pharmaceutical segment, with revenue increasing by 39% year-over-year to $80.5 million, boosted by higher product sales and milestone payments from collaborations.\n2. Significant progress in OPKO's proprietary ModeX pipeline, with two programs entering Phase 1 clinical trials, including a tetraspecific antibody (MDX-2001) for solid tumors and a nanoparticle vaccine for Epstein-Barr Virus (EBV) in collaboration with Merck.\n3. Improved financial position and capital structure, supported by a $50 million upfront payment from the Merck collaboration and the sale of GeneDx, allowing OPKO to fund its pipeline advancement and initiate share buybacks.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}